1 ression of secondary hyperparathyroidism and renal osteodystrophy.

2 eatment of secondary hyperparathyroidism and renal osteodystrophy.

3  shown to ameliorate the skeletal lesions of renal osteodystrophy.

4 st of the metabolic abnormalities that cause renal osteodystrophy.

5  including severe cardiovascular disease and renal osteodystrophy.

6 s could be used to improve the management of renal osteodystrophy.

7 ssociated the adynamic bone disorder form of renal osteodystrophy.

8 ficacious agent in treating animal models of renal osteodystrophy.

9 t reaching far beyond traditional notions of renal osteodystrophy and hyperparathyroidism.

10 onic kidney disease, vascular calcification, renal osteodystrophy, and phosphate contribute substanti

11                           Five patients with renal osteodystrophy developed marked hyperostosis of th

12 rathyroid bone disease, the major variety of renal osteodystrophy, from developing in patients with r

13 n the premenopausal group, and patients with renal osteodystrophy had higher BW (41.4% +/- 9.6) than

14              These are related to underlying renal osteodystrophy, hypophosphatemia, and immunosuppre

15                          The pathogenesis of renal osteodystrophy is related to phosphate retention,

16  that latter analog, currently used to treat renal osteodystrophy, is more efficacious than 1,25(OH)2

17 ally to low- or high-turnover bone may treat renal osteodystrophy more effectively.

18          Uremic mice exhibited high turnover renal osteodystrophy; treatment with sevelamer significa